Ligand Pharmaceuticals and the SALK Institute Enter Settlement Agreement and Mutual Release of All ClaimsSettlement Agreement and Mutual Release of All Claims • April 19th, 2021
Contract Type FiledApril 19th, 2021Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and The Salk Institute for Biological Studies (SALK) have entered into a Settlement Agreement and Mutual Release of All Claims (Settlement Agreement). Through the Settlement Agreement, the parties have resolved all disputes that have arisen between them including SALK's primary claim in arbitration